Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia.

Leukemia & lymphoma - 1 Aug 2020

Han Heejoo, Shin Dong-Yeop, Kim Dongchan, Kim Hyungsuk, Lee Chansup, Koh Youngil, Hong Junshik, Yoon Sung-Soo

Abstract excerpt

Leukemic stem cells (LSCs) are a major cause of treatment failure and recurrence of acute myeloid leukemia (AML). Targeting LSC is essential to developing a potential cure for patients with relapsed/refractory AML. Here we investigated the effect of aryl hydrocarbon receptor (AhR) signaling on AML stem/progenitor proportion and examined the combined effect of AhR agonist and tyrosine kinase inhibitor. The AhR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Cell Differentiation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Pyrazines

Share to Receptors, Aryl Hydrocarbon

Source

Identifiers

PMID: 32374198
DOI: 10.1080/10428194.2020.1747062

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia.PMID 32374198Read ↗

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.Semantic proximity Read ↗

Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.Semantic proximity Read ↗

Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemiaSemantic proximity Read ↗

4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition.Semantic proximity Read ↗

Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemiaSemantic proximity Read ↗

All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivoSemantic proximity Read ↗

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.Semantic proximity Read ↗

Activation of AhR with nuclear IKKα regulates cancer stem-like properties in the occurrence of radioresistance.Semantic proximity Read ↗

Identification of the Benzoimidazole Compound as a Selective FLT3 Inhibitor by Cell-Based High-Throughput Screening of a Diversity LibrarySemantic proximity Read ↗

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia.Semantic proximity Read ↗

Targeting the aryl hydrocarbon receptor nuclear translocator complex with DMOG and Stemregenin 1 improves primitive hematopoietic stem cell expansion.Semantic proximity Read ↗

Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.